Blog

September 15, 2021September 15, 2021

Aequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology Expertise

Aequus Pharmaceuticals (Aequus) a speciality pharmaceutical company, announces that Dr. Robert K. Koenekoop MD, MSc, PhD, FRCS(C), FARVO has joined as a medical and clinical consultant to Aequus on inherited retinal diseases, and specifically to support Aequus’ collaboration with reVision Therapeutics for the product REV-0100, a potential therapy for Stargardt disease.

Dr. Koenekoop is a Pediatric Ophthalmologist and Director of Pediatric Ophthalmology and Molecular Biology of Blindness at the Montreal Children’s Hospital (MCH). He also holds positions as Professor of Paediatric Surgery, Human Genetics and Adult Ophthalmology at McGill University and Director of the Laboratory for Retinal Genetics and Therapeutics, and Chief of Paediatric Ophthalmology at MCH Glen site.

Dr. Koenekoop brings over 25 years of national and international basic and clinical research expertise in ophthalmology, in both children and adults. With Dr. Koenekoop’s expert background and medical practice in Canada for inherited retinal diseases, his valuable insights will help the REV-0100 programme move forward.

“Stargardt macular dystrophy and all the other inherited retinal degenerations were deemed untreatable by the discoverers of these diseases and many generations of clinical teachers and researchers in this field,” said Dr. Koenekoop. “It is very exciting after all these years of seeing patients’ vision decline, that now for the first time we are seeing stabilization and even improvements in vision with some of the experimental agents.”

REV-0100 is a potential therapy for patients with Stargardt disease that is designed to bind and clear a toxic lipid called lipofuscin. Accumulation of lipofuscin in Stargardt disease leads to cell death and retinal degeneration. REV-0100 has the potential to reduce lipofuscin levels in the retina.

Click HERE for the full press release.

Earlier in August, Aequus announced a collaboration with reVision Therapeutics- See full press release HERE.

September 14, 2021September 13, 2021

WCO Launches Myopia Management Online Resource

World Council of Optometry and CooperVision logos

The World Council of Optometry (WCO) and CooperVision have jointly developed an easy-to-use online resource that provides multilingual assets and approaches that will enable eye care professionals to apply a standard of care to manage the condition. The resource site is live and can be found HERE.

“This online resource provides eye care practitioners from anywhere in the world access to the information they need to implement a standard of care to treat or manage a patient’s myopia progression,” said Paul Folkesson, president, World Council of Optometry. “Thanks to the support of CooperVision, information regarding the treatment of myopia is more accessible than ever before. This is just the start as we work to provide more materials and educational programming through this collaborative partnership.”

The myopia online resource was developed to serve as a valuable point to provide information that has not been easily accessible and provide a forum to encourage the exchange of knowledge and experiences within the global optometric community. The site is organized around the three main pillars of the evidence-based standard of care unanimously adopted by the WCO Board of Directors—mitigation, measurement and management. Each pillar provides a listing of papers and studies that have been distilled into one-page “Myopia Moments” that are available in Arabic, Chinese, English, French, Russian and Spanish. Visitors to the site can download a Myopia Moment—giving them evidence-based guidance about providing care to a patient—or they can learn more by accessing the many papers and studies that have been aggregated from independent third-party sources.

Click HERE for the full press release.

September 13, 2021September 13, 2021

Safilo and Chiara Ferragni Sign New Licensing Agreement for Eyewear Collection

Safilo and Chiara Ferragni, entrepreneur and global fashion icon, announce their new multi-year global licensing agreement for the design, manufacture and distribution of the first Chiara Ferragni branded eyewear collection.

The full eyewear range – both optical and sun – will be unveiled for the SS22 season, hitting the market in January 2022.

“We are excited to welcome to our portfolio one of the most famous and powerful digital entrepreneurs in the world,” declared Angelo Trocchia, CEO of Safilo Group. “Together, we want to create a new leading and digitally boosted fashion eyewear brand that directly speaks to new generations, working in synergy with the extraordinary power of Chiara’s global fan base to further strengthen the presence of Safilo in the digital universe.”

“Safilo represents not only excellence in eyewear but also, similarly to my brand, a great example of Italian spirit with a global reach,” stated Chiara Ferragni, CEO and Creative Director of Chiara Ferragni brand. “They strongly believed in my brand and in developing this new category.”

Over the past months, Safilo has been accelerating on its digital transformation projects, working to be at the forefront of seizing the opportunities of the digital business and making significant progress in terms of product offer, service level, customer engagement and digital connection. The new agreement with Chiara Ferragni, marking her namesake brand’s entry into eyewear licensing, goes in this same direction of digital transformation and active engagement strategy, addressing new generations through new languages and channels to reflect what is happening in the marketplace.

Click HERE for the full press release.

Etnia Barcelona Launches Mambo Vol.1 Collection

The new Etnia Barcelona Mambo Collection is, by nature, optimistic, eclectic, and unique. Crafted details and painstakingly worked laminations all go to make up these geometrical maxiglasses, created in natural acetate and with their “form within a form” effect enhanced by the superpositoning of contrasting colours. Vibrant hues create a delicate effect, all put together with leading edge technology.

Featured model: Mambo 5

Distributed by: www.etniabarcelona.com

September 10, 2021September 12, 2021

Crizal Rock: Combination Against Scratches and Smudges Available in Finished Single Vision Lenses

Ever since the first Crizal® coating was created more than 29 years ago, Essilor’s teams have continued to innovate and develop increasingly high-performance lens coatings.

Crizal® RockTM: Durability Like Never Before

On September 1, 2020, our Crizal® Rock™ coating, which offers the best combination against scratches and smudges, became available on surfaced lenses. Essilor announces that Crizal® Rock™ will be available for finished single vision lenses as of September 14, 2021.

Thanks to the unique High-Resistance Technology, the newest addition to the Crizal® family line is a shield that combines scratch resistance (among the best on the market), and ease of cleaning, along with all the benefits of the original Crizal® coating: high glare reduction, increased protection against UV rays (back side), anti-dust and superior water-repellent properties.

Crizal® coatings are designed to take on all of these day-to-day hazards. The Crizal® Rock™ coating offers optimal visual comfort and will meet all of the everyday needs of eyeglass wearers.

Information and Marketing Tools for ECPs

Crizal® Rock™ offers three times more scratch resistance than the Crizal® entry-level coatings. Learn more

Click HERE for the full press release.